| Bioactivity | ARD-2051 is a potent and orally active androgen receptor (AR) proteolysis-targeting chimera degrader. ARD-2051 achieves DC50 values of 0.6 nM for AR protein degradation in both the LNCaP and VCaP prostate cancer cell lines. ARD-2051 can be used for the research of prostate cancer[1]. |
| Target | DC50: 0.6 nM (AR protein degradation) |
| Name | ARD-2051 |
| CAS | 2632305-17-8 |
| Formula | C43H45ClN8O5 |
| Molar Mass | 789.32 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Han X, et al. Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer. J Med Chem. 2023 Jul 13;66(13):8822-8843. |
ARD-2051
CAS: 2632305-17-8 F: C43H45ClN8O5 W: 789.32
ARD-2051 is a potent and orally active androgen receptor (AR) proteolysis-targeting chimera degrader. ARD-2051 achieves
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.